BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,926,834 | +111.1% | 1,825,824 | +109.9% | 0.00% | 0.0% |
| Q2 2023 | $6,123,371 | -54.4% | 869,797 | -46.0% | 0.00% | 0.0% |
| Q1 2023 | $13,432,988 | +1.2% | 1,610,670 | +39.4% | 0.00% | -50.0% |
| Q4 2022 | $13,267,791 | +15.8% | 1,155,731 | +27.1% | 0.00% | 0.0% |
| Q3 2022 | $11,457,000 | -75.3% | 909,269 | -79.2% | 0.00% | -66.7% |
| Q2 2022 | $46,294,000 | +301.0% | 4,375,569 | +516.2% | 0.01% | +200.0% |
| Q1 2022 | $11,545,000 | +121.5% | 710,047 | +88.7% | 0.00% | +100.0% |
| Q4 2021 | $5,213,000 | -14.7% | 376,369 | -11.5% | 0.00% | 0.0% |
| Q3 2021 | $6,114,000 | -57.6% | 425,377 | -53.4% | 0.00% | -50.0% |
| Q2 2021 | $14,423,000 | +451.3% | 912,205 | +254.7% | 0.00% | – |
| Q1 2021 | $2,616,000 | +27.5% | 257,207 | -6.5% | 0.00% | – |
| Q4 2020 | $2,051,000 | +208.9% | 275,147 | +42.3% | 0.00% | – |
| Q3 2020 | $664,000 | -34.4% | 193,397 | -8.9% | 0.00% | – |
| Q2 2020 | $1,012,000 | -26.8% | 212,393 | -69.3% | 0.00% | – |
| Q1 2020 | $1,383,000 | -21.2% | 692,148 | +36.0% | 0.00% | – |
| Q4 2019 | $1,756,000 | -50.9% | 509,067 | -59.2% | 0.00% | -100.0% |
| Q3 2019 | $3,576,000 | -33.2% | 1,248,316 | -11.6% | 0.00% | 0.0% |
| Q2 2019 | $5,354,000 | +79.3% | 1,412,653 | +285.1% | 0.00% | 0.0% |
| Q1 2019 | $2,986,000 | +101.3% | 366,784 | +99.7% | 0.00% | – |
| Q4 2018 | $1,483,000 | +0.9% | 183,703 | -4.7% | 0.00% | – |
| Q3 2018 | $1,470,000 | +6.3% | 192,719 | -20.1% | 0.00% | – |
| Q2 2018 | $1,383,000 | -34.3% | 241,329 | -45.3% | 0.00% | -100.0% |
| Q1 2018 | $2,106,000 | +10.4% | 441,431 | +13.6% | 0.00% | 0.0% |
| Q4 2017 | $1,908,000 | +0.5% | 388,705 | +7.3% | 0.00% | 0.0% |
| Q3 2017 | $1,898,000 | +7.4% | 362,140 | +13.9% | 0.00% | 0.0% |
| Q2 2017 | $1,768,000 | -77.8% | 317,899 | -66.5% | 0.00% | 0.0% |
| Q1 2017 | $7,966,000 | +91.9% | 948,370 | +44.6% | 0.00% | 0.0% |
| Q4 2016 | $4,152,000 | +3607.1% | 655,930 | +2490.3% | 0.00% | – |
| Q3 2016 | $112,000 | +133.3% | 25,323 | +50.8% | 0.00% | – |
| Q2 2016 | $48,000 | -90.6% | 16,794 | -90.7% | 0.00% | – |
| Q1 2016 | $510,000 | -52.4% | 180,225 | +73.6% | 0.00% | – |
| Q4 2015 | $1,071,000 | +3.1% | 103,804 | +13.9% | 0.00% | – |
| Q3 2015 | $1,039,000 | -29.7% | 91,158 | -8.0% | 0.00% | -100.0% |
| Q2 2015 | $1,479,000 | +65.8% | 99,092 | +0.3% | 0.00% | – |
| Q1 2015 | $892,000 | +19.7% | 98,765 | +61.4% | 0.00% | – |
| Q4 2014 | $745,000 | -73.6% | 61,194 | -78.8% | 0.00% | -100.0% |
| Q3 2014 | $2,819,000 | -55.0% | 288,216 | -41.3% | 0.00% | -50.0% |
| Q2 2014 | $6,261,000 | +12.6% | 491,034 | -6.5% | 0.00% | 0.0% |
| Q1 2014 | $5,559,000 | +37.2% | 525,306 | -1.4% | 0.00% | 0.0% |
| Q4 2013 | $4,051,000 | +644.7% | 533,012 | +612.3% | 0.00% | – |
| Q3 2013 | $544,000 | +95.7% | 74,833 | -58.3% | 0.00% | – |
| Q2 2013 | $278,000 | – | 179,327 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |